Research Paper Volume 12, Issue 9 pp 8728—8741

High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer

Figure 1. PRMT5 expression in bladder cancer in the Oncomine and The Cancer Genome Atlas (TCGA) databases. (A–C) Comparison of the PRMT5 expression levels in the Dyrskjot Bladder 3 and Sanchez-Carbayo Bladder 2 data sets of the Oncomine database. The threshold: P value: 1E-4, fold change: 1.5, gene rank: 10%. (D) A median-ranked analysis of the Dyrskjot Bladder 3 (1, 2) and Sanchez-Carbayo Bladder 2 (3) data sets from the Oncomine database. The colored squares revealed the median rank for PRMT5 across the three analyses (vs normal tissue). (E) Comparison of the PRMT5 expression level in bladder cancer and the normal tissue from the TCGA database. (F, G) Overall and progression-free survival times in bladder cancer patients with low versus high expression of PRMT5 assessed by Kaplan-Meier analysis from the TCGA cohorts. SBC: superficial bladder cancer, IBUC: infiltrating bladder urothelial carcinoma.